Rowett Institute of Nutrition and Health, University of Aberdeen
Aberdeen, AB21 9SB, United Kingdom
NCT Number: NCT01241474
The purpose of this study is to determine whether a prolonged (9 month) high (6g/d) of marine oil improves insulin sensitivity and glucose control in subjects with impaired glucose regulation.
Looking for future studies?
Notify Me40 year–69 year
All sexes
Interventional
Not applicable
Aberdeen, AB21 9SB, United Kingdom
The incidence of Type 2 diabetes is related both to age and obesity. The disease impacts on quality of life and treatments represent a major health cost. Prevention or delayed onset of the disease remains a key target. Animal studies have shown that provision of high amounts of fish oil in the diet improves insulin sensitivity but human trials have proved equivocal. Recent dose-response trials in animals have shown the improved insulin sensitivity only occurs when the proportion of n-3 long chain polyunsaturated fatty acids (n-3 PUFA), docosahexaenoic acid and eicosapentaenoic acid, exceeds 14% of the total phospholipid fraction within tissue cell membranes. To achieve such values in humans would require a high dose of n-3 PUFA supplied over a prolonged period of time. This is tested within the current study where a daily dose of 6 g day of fish oil (containing a total of 3g docosahexaenoic acid plus eicosapentaenoic acid) is supplied for 9 months. As well as improving control of glycemia increased insulin sensitivity may also enhance protein metabolism and reduce the impact of frailty in older subjects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
Other names: EPAX 6000TG code F0-5222/XT
6 x 1g capsules per day for 9 months
Other names: Banner chemicals product GL-518/XT
Time frame: 0 months and 9 months
Time frame: at monthly intervals between 0 and 9 months
Time frame: 0, 4 and 9 months
University of Aberdeen
Other
Chronic Long-chain n-3 PUFA Supplement and Insulin Action in Human Subjects With Impaired Glucose Regulation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02850562
Atrophy, Body Weight
View Trial DetailsNCT06543706
Body Weight, Brain Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT00005374
Cardiovascular Diseases, Coronary Disease
View Trial DetailsNCT00005365
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details